[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:
10.1177/1060028018797110[2] DAVID J. AUGERI. Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes[J]. Journal of Medicinal Chemistry, 2005, 48 15: 5025-5037. DOI:
10.1021/jm050261p[3] CHINTAN N. KOYANI . Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure[J]. Biochemical pharmacology, 2017, 145: Pages 64-80. DOI:
10.1016/j.bcp.2017.08.021
